Amid Shortages, US Allows Expanded Production of ADHD Drug Vyvanse - Clinical Advisor
The DEA approved Takeda Pharmaceuticals to increase Vyvanse production by 24% to address ongoing ADHD drug shortages, with a 13,478-pound increase including 3434 pounds for domestic and 10,313 pounds for foreign demand.
Highlighted Terms
Related News
Amid Shortages, US Allows Expanded Production of ADHD Drug Vyvanse - Clinical Advisor
The DEA approved Takeda Pharmaceuticals to increase Vyvanse production by 24% to address ongoing ADHD drug shortages, with a 13,478-pound increase including 3434 pounds for domestic and 10,313 pounds for foreign demand.